These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1540 related articles for article (PubMed ID: 28924019)

  • 21. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
    Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
    Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Need for standardization of cytokine profiling in CAR T cell therapy.
    Biery DN; Turicek DP; Diorio C; Schroeder BA; Shah NN
    Mol Ther; 2024 Sep; 32(9):2979-2983. PubMed ID: 38532629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.
    Dholaria BR; Bachmeier CA; Locke F
    BioDrugs; 2019 Feb; 33(1):45-60. PubMed ID: 30560413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
    Hill JA; Li D; Hay KA; Green ML; Cherian S; Chen X; Riddell SR; Maloney DG; Boeckh M; Turtle CJ
    Blood; 2018 Jan; 131(1):121-130. PubMed ID: 29038338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.
    Brammer JE; Braunstein Z; Katapadi A; Porter K; Biersmith M; Guha A; Vasu S; Yildiz VO; Smith SA; Buck B; Haddad D; Gumina R; William BM; Penza S; Saad A; Denlinger N; Vallakati A; Baliga R; Benza R; Binkley P; Wei L; Mocarski M; Devine SM; Jaglowski S; Addison D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
    He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A safe and potent anti-CD19 CAR T cell therapy.
    Ying Z; Huang XF; Xiang X; Liu Y; Kang X; Song Y; Guo X; Liu H; Ding N; Zhang T; Duan P; Lin Y; Zheng W; Wang X; Lin N; Tu M; Xie Y; Zhang C; Liu W; Deng L; Gao S; Ping L; Wang X; Zhou N; Zhang J; Wang Y; Lin S; Mamuti M; Yu X; Fang L; Wang S; Song H; Wang G; Jones L; Zhu J; Chen SY
    Nat Med; 2019 Jun; 25(6):947-953. PubMed ID: 31011207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
    Juluri KR; Wu QV; Voutsinas J; Hou J; Hirayama AV; Mullane E; Miles N; Maloney DG; Turtle CJ; Bar M; Gauthier J
    Blood Adv; 2022 Apr; 6(7):2055-2068. PubMed ID: 34666344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
    Dos Santos DMC; Rejeski K; Winkelmann M; Liu L; Trinkner P; Günther S; Bücklein VL; Blumenberg V; Schmidt C; Kunz WG; Von Bergwelt-Baildon M; Theurich S; Subklewe M
    Haematologica; 2022 Sep; 107(9):2096-2107. PubMed ID: 35172565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.
    Jiang H; Liu L; Guo T; Wu Y; Ai L; Deng J; Dong J; Mei H; Hu Y
    Ann Hematol; 2019 Jul; 98(7):1721-1732. PubMed ID: 31055613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
    Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
    Hu Y; Sun J; Wu Z; Yu J; Cui Q; Pu C; Liang B; Luo Y; Shi J; Jin A; Xiao L; Huang H
    J Hematol Oncol; 2016 Aug; 9(1):70. PubMed ID: 27526682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The occurrence of cytokine release syndrome and its impact on the prognosis of patients with relapsed and refractory multiple myeloma following chimeric antigen receptor T-cell therapy].
    Nian L; Jie XX; Zhang LW; Yan ZL; Qi KM; Zhang HX; Xu KL; Cheng H; Li ZY
    Zhonghua Yi Xue Za Zhi; 2024 Aug; 104(33):3148-3153. PubMed ID: 39168846
    [No Abstract]   [Full Text] [Related]  

  • 36. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
    Liu Y; Chen X; Wang D; Li H; Huang J; Zhang Z; Qiao Y; Zhang H; Zeng Y; Tang C; Yang S; Wan X; Chen YH; Zhang Y
    J Immunother; 2018; 41(9):406-410. PubMed ID: 30198955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
    Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
    Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous CD19-Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis.
    Nicolai R; Merli P; Moran Alvarez P; Bracaglia C; Del Bufalo F; Marasco E; Caiello I; Prencipe G; Algeri M; Cefalo MG; Becilli M; Quintarelli C; Sinibaldi M; Hanssens L; De Benedetti F; Locatelli F
    Arthritis Rheumatol; 2024 Oct; 76(10):1560-1565. PubMed ID: 38924652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report.
    Liang Z; Zhang H; Shao M; Cui Q; Wu Z; Xiao L; Huang H; Hu Y
    Medicine (Baltimore); 2020 Oct; 99(43):e22510. PubMed ID: 33120740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 77.